Komori
Revision of earnings forecasts7459MEDIPAL HOLDINGS CORPORATIONTrading & Wholesale

Notice Regarding Revisions to Full-Year Consolidated Earnings Forecast

The sales forecast was left unchanged, while operating profit and ordinary profit were revised downward to reflect the increase in profit attributable to the parent company following the acquisition of all shares of PALTAC and the expected tender offer-related expenses and interest costs associated with financing. Net income attributable to owners of the parent was revised upward.

Worth reading
71In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
4000
¥ million (changes in ordinary profit and net income attributable to owners of the parent)
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

the fiscal year ending March 2027 · Full yearPrevious forecast published 14 May 2026
Net Sales—→—million
—
Operating profit—→—million
—
Ordinary income—→—million
—
Profit attributable to owners of the parent—→—million
—
Net income per share—→—
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document.

Reason for the revision

After the tender offer for PALTAC shares ended, the Company proceeded with making PALTAC a wholly owned subsidiary, causing profits previously attributable to non-controlling interests to accrue to the Company. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while interest and other costs associated with financing are expected to be incurred as financial expenses. These items have been reflected in the forecast.

Previous-period resultsSales ¥3,817,354 million, operating profit ¥53,182 million, ordinary profit ¥75,723 million, net income attributable to owners of the parent ¥42,534 million, and basic earnings per share of ¥206.67 (fiscal year ended March 2026)
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales3,944,000 → 3,944,000
Operating profit55,000 → 53,500(△2.7%)
Ordinary income71,500 → 67,500(△5.6%)
Profit attributable to owners of the parent39,000 → 43,000(10.3%)
Net income per share190.52 → 210.06
Fiscal Period Coveredthe fiscal year ending March 2027
Period CoveredFull year
Publication date of previous forecast14 May 2026
Previous-period resultsSales ¥3,817,354 million, operating profit ¥53,182 million, ordinary profit ¥75,723 million, net income attributable to owners of the parent ¥42,534 million, and basic earnings per share of ¥206.67 (fiscal year ended March 2026)
Reason for the revisionAfter the tender offer for PALTAC shares ended, the Company proceeded with making PALTAC a wholly owned subsidiary, causing profits previously attributable to non-controlling interests to accrue to the Company. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while interest and other costs associated with financing are expected to be incurred as financial expenses. These items have been reflected in the forecast.
Consolidated / non-consolidatedConsolidated
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The tender offer for PALTAC shares has ended, and as the Company proceeds with making PALTAC a wholly owned subsidiary, profits previously attributable to non-controlling interests will accrue to the Company. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while interest and other costs associated with financing are expected to be incurred as financial expenses. These items have been reflected in the earnings forecast.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Revisions to Full-Year Consolidated Earnings Forecast | MEDIPAL HOLDINGS CORPORATION (7459) timely disclosure | Komori